Impact of protein corona and PEGylation on the accumulation and efficacy of lysosome-disrupting lipid nanoparticles in KRAS-mutated cancer.

Nanomedicines offer promising approaches for targeted drug delivery to tumor cells but their clinical translation is hindered by limited delivery efficacy in heterogenous clinical tumors. Protein corona adsorbed to the surface of nanoparticles (NPs) would cause opsonization and accelerate blood clearance, posing a significant barrier to effective drug delivery. Polyethylene glycol (PEG) modification is widely employed to prolong the NPs' circulation time and improve the delivery efficacy. Nevertheless, the clinical efficacy of PEG-based nanomedicines is still debatable. Here, we prepared non-PEGylated lysosomal-disrupting dimeric chloroquine (CQ) lipid nanoparticles (DCLNPs) and PEGylated DCLNPs (PEG-DCLNPs) and systematically studied the impact of PEGylation on DCLNPs' delivery efficacy in KRAS -mutant (MT) and -wildtype (WT) cancers. We found that the protein corona facilitates KRAS -MT cancer-specific targeted delivery of DCLNPs by exploiting extracellular protein engulfment preference. In contrast, PEGylation hindered delivery and efficacy of DCLNPs. Proteomics analysis highlighted apolipoproteins, particular apolipoprotein E, as key factors promoting the uptake of DCLNPs. Additionally, DCLNPs sensitized immunosuppressive KRAS -MT cancers to anti-PD1 immunotherapy. These results underscore the importance of comprehending the context-dependent role of the protein corona in regulating nanoparticle biodistribution, suggesting that PEGylation may not be suitable across all cancer types. [Display omitted] • Protein corona selectively promotes accumulation of DCLNPs in KRAS -MT cancer cells. • PEGylation of DCLNPs decreases accumulation and cytotoxicity in KRAS -MT cancers. • Proteomics analysis unveiles apolipoproteins critical for the accumulation of DCLNPs in KRAS -MT cancers. • DCLNPs remodeled the suppressive immune microenvironment of KRAS -MT cancers. [ABSTRACT FROM AUTHOR]

Copyright of Nano Today is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)